• FREE

    Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy

    The goal of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy is to help you to discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies in the treatment of multiple myeloma.

    By the end of Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy, you will be able to:
    • Recall updates in the staging, prognosis, and diagnosis of MM.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
    • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.

    Target Audience:
    Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: November 02, 2017
    • Expiration of CME credit: November 02, 2019
  • FREE

    Risky Business: Diagnosing and Treating Invasive Fungal Infections

    Risky Business: Diagnosing and Treating Invasive Fungal Infections consists of 3 brief lectures on the diagnosis and treatment of invasive fungal infection:

    After completing Risky Business: Diagnosing and Treating Invasive Fungal Infections, you should be better able to:
    • Describe the epidemiology and burden of invasive fungal infections in patients who are immunocompromised and/or Immunosuppressed.
    • Incorporate the latest diagnostic techniques for invasive fungal infections to ensure that the appropriate therapy can be initiated in a timely manner.
    • Integrate the latest evidence-based treatment guidelines and clinical data pertaining to the efficacy, safety, and prophylactic use of antifungal agents to optimize the management of invasive fungal infections.

    Target Audience:
    Hematologist-oncologists, medical oncologists, transplant surgeons, critical care surgeons, critical care pulmonologists, and other health care professionals involved in the treatment of patients with or at risk for invasive fungal infections.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Vindico Medical Education
    • Format: On-Demand Online, Online Video
    • Material last updated: April 18, 2017
    • Expiration of CME credit: April 17, 2018
  • FREE

    ScientiaCME Treatment strategies in Gaucher disease

    At the conclusion of By the end of Treatment strategies in Gaucher disease, you will be able to:
    • Describe the importance of appropriate GD (Gaucher Disease) diagnosis and treatment (use • for bullets)
    • Determine the likelihood of GD using with established diagnosis methods, given a patient case
    • Describe present therapies for the treatment of GD and the literature supporting their use
    • Design a medical plan to treat a patient with GD, taking into account presently available therapies

    Target Audience:
    Physicians focusing on Cardiology, genetic disorders, hematology, oncology, orthopedics, gastroenterology, neurology and pediatrics.

    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: February 12, 2017
    • Expiration of CME credit: February 12, 2019
  • FREE

    Multiple Myeloma (MM): Highlights from the American Society for Clinical Oncology (ASCO) 2018

    This free online CME program covers key learnings around Multiple Myeloma from the American Society for Clinical Oncology 2018 Conference.

    After completing this course, physicians will better be able to:

    • Summarize the most impactful findings presented at ASCO 2018 relating to Multiple myeloma and apply them to patient cases, taking into account any relevant barriers to care.
    • Additional objectives to be dictated by clinical content

    Target Audience: The following healthcare professionals: hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 19, 2018
    • Expiration of CME credit: July 19, 2020
  • FREE

    Hemophilia B: Therapeutic Updates, Emerging Therapies, and Barriers to Care

    This free online CME course provides clinical insights about Hemophilia B and helps physicians better treat the condition.

    Topics covered include:

    • Updates in the epidemiology and diagnosis of hemophilia B
    • Current and emerging treatment options for hemophilia B
    • Challenges in care in hemophilia B

    After completing this course, you will better be able to:

    • Describe the pathophysiology of hemophilia B, with an emphasis on characteristics that play a role in determining the staging, prognosis, and diagnosis
    • Describe the benefits of prophylactic vs. on-demand clotting factor regimens in patients with hemophilia and apply them inpatient cases
    • Describe emerging therapies in the treatment of hemophilia B
    • Individualize treatments in patients with hemophilia B by taking into account treatment modalities, recent clinical trial evidence, and barriers to care, including inhibitors

    Target audience: Hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other clinicians with an interest in hemophilia B.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: May 08, 2018
    • Expiration of CME credit: May 08, 2020
  • FREE

    Hemophilia A: Therapeutic Updates, Emerging Therapies, and Barriers to Care

    This free CME activity will give physicians the latest insights around Hemophilia A and will them better treat patients who are plagued by the disease.

    Topics covered in this course includes:

    • Updates in the epidemiology and diagnosis of hemophilia A
    • Current and emerging treatment options for hemophilia A
    • Challenges in care in hemophilia A

    After completing this activity, physicians will better be able to:

    • Describe the pathophysiology of hemophilia A, with an emphasis on characteristics that play a role in determining the staging, prognosis, and diagnosis
    • Describe the benefits of prophylactic vs. on-demand clotting factor regimens in patients with hemophilia and apply them in patient cases
    • Describe the emerging therapies in the treatment of hemophilia A
    • Individualize treatments in patients with hemophilia A by taking into account treatment modalities, recent clinical trial evidence, and barriers to care , including inhibitors

    Target Audience: Hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other clinicians with an interest in hemophilia A.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 17, 2018
    • Expiration of CME credit: March 17, 2020
  • FREE

    Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices

    This free online CME program takes a deep look into Diffuse large B-cell lymphoma (DLBCL) and provides insights that will lead to better treatment for patients who suffer from the condition.

    Topics covered in this CME activity include:,

    • Epidemiology and diagnosis of DLBCL
    • Management of DLBCL: current guidelines, agents, and monitoring
    • DLBCL Best practices

    After completing thise course, you will better be able to:

    • Recognize and describe those characteristics that play a role in determining the staging, prognosis, and diagnosis of diffuse large B-cell lymphoma (DLBCL)
    • Describe the most approaches to DLBCL management and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence and evidence-based treatment guidelines supporting them
    • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of DLBCL
    • Describe the challenges and barriers to care associated with treating patients with DLBCL

    Target Audience: Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with DLBCL.

    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 16, 2018
    • Expiration of CME credit: March 16, 2020